title: [Pleotropic Effects of Atorvastatin in Patients With Chronic Ischemic Heart Disease].
abstract: Examined 52 patients with a diagnosis Ischemic heart disease: stable angina II-III FC CHF I-IIA stage, in combination with hypercholesterolemia aged 53-65 years (58,2+/-6,5), receiving together with traditional antianginal therapy generic atorvastatin Torvakard in the dose of 10 mg/day (20 people) with the level of total cholesterol from 5.0 to 6.50 mmol/l, patients with cholesterol levels from is 6.51 to 8.0 mmol/l was taking Torvakard 20 mg/day (32 person). As a result of 3 months therapy with low doses of Torvakarda decreased level of CRP, endothelin-1, IMT, improving the parameters of endothelium-dependent vasodilation, which shows the positive impact of the drug on morphological and functional parameters of the vascular wall.
authors.affiliation: Kursk State Medical University, Kursk, Russia.
authors.forename: V P
authors.initials: VP
authors.lastname: Mikhin
authors.affiliation: Kursk State Medical University, Kursk, Russia.
authors.forename: Yu A
authors.initials: YA
authors.lastname: Zhilyaeva
authors.affiliation: Kursk State Medical University, Kursk, Russia.
authors.forename: N I
authors.initials: NI
authors.lastname: Gromnaky
mesh_terms: D000368:Aged; D000924:Anticholesteremic Agents; D000069059:Atorvastatin; D008078:Cholesterol, LDL; D006538:Heptanoic Acids; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D006937:Hypercholesterolemia; D008875:Middle Aged; D017202:Myocardial Ischemia; D011758:Pyrroles
chemical_list: D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D000069059:Atorvastatin